InvestorsHub - NYSE, NASDAQ, AMEX, OTCBB, Pink Sheet Stock Message Boards, Stock Charts, Stock Quotes, Level II and Market News

Ticker	Name	Price	Change	Change %	Volume	Posts
ICCT	iCoreConnect Inc	0.7599	0.4628	155.81%	53,442,819	3,637
CTOR	Citius Oncology Inc	1.12	0.4550	68.42%	25,112,232	94
CRWS	Crown Crafts Inc	5.79	2.10	56.91%	315	44
NWTG	Newton Golf Company Inc	2.16	0.6700	44.97%	11,062,376	1
TGL	Treasure Global Inc	0.1088	0.0288	36.00%	52,070,537	215
ECBK	ECB Bancorp Inc	19.99	4.75	31.12%	12
AFRI	Forafric Global PLC	11.00	2.46	28.81%	4
COOP	Mr Cooper Group Inc	132.56	28.07	26.86%	129,088	740,380
HAO	Haoxi Health Technology Ltd	1.83	0.3800	26.21%	52	11
TWIN	Twin Disc Inc	9.95	2.00	25.16%	19	9

Ticker	Board Name	Price	Change %	Posts (24h)
LWLG	Lightwave Logic Inc	1.13	-5.83%	37
AVXL	Anavex Life Sciences Corp	8.51	-2.41%	43
COOP	Mr Cooper Group Inc	132.41	+26.72%	46
LQMT	Liquidmetal Technologies Inc	0.0788	0.00%	18
LEHNQ	Lehman Brothers Financial SA	0.0003	0.00%	5
VPLM	Voip Pal Com Inc	0.0095	0.00%	10

	Board Name	Posts (24h)
	ORIONS Money Stocks	16
	DD Support Board and Research Team	16
	BBs Stock Haven	28
4	Savvy Trades and Investments	5
5	MOMOS BREAKOUT BOARD	14
6	Mining Sector Ideas	19

Ticker	Name	Price	Change %	Market Cap	Volume ($)
BTC	Bitcoin	82,117.31	-0.27%	1,629.5B	2.2B	Message Board Quote News
ETH	Ethereum	1,812.81	0.40%	218.6B	1.4B	Message Board Quote News
USDT	Tether USD	0.99987	0.00%	141.9B	172.1M	Message Board Quote News
XRP	Ripple	2.08	-2.80%	120.1B	731.6M	Message Board Quote News
BNB	Binance Coin	596.19	-0.91%	94.1B	162.3M	Message Board Quote News
SOL	Solana	123.96	-0.51%	60.7B	557.2M	Message Board Quote News
USDC	USD Coin	0.9999	0.00%	56.1B	838.8M	Quote News
DOGE	Dogecoin	0.16323	-1.76%	24.2B	267.5M	Message Board Quote News
ADA	Cardano	0.6431	-2.68%	23.1B	131.8M	Message Board Quote News
TRX	TRON	0.233571	1.12%	20.1B	87.6M	Message Board Quote News

Play Episode

7min

Proactive - Interviews for investors

Chesnara CEO discusses strong 2024 results, dividend growth and M&A outlook

Chesnara PLC (LSE:CSN) CEO Steve Murray talked to Proactive's Stephen Gunnion about the company’s strong 2024 full-year results, highlighting robust cash generation and consistent dividend growth. Murray highlighted that Chesnara generated £60 million in cash over the year, providing strong dividend coverage and supporting its 20-year track record of uninterrupted dividend growth. The business also increased its overall value and maintained a strong solvency position. The interview also covered Chesnara’s acquisition strategy, with Murray detailing the second Canada Life deal, which delivered an uplift in economic value to £11 million—higher than the £8 million initially expected—off a £2 million consideration. He explained that Chesnara currently holds around £200 million in acquisition firepower, supported by a solvency capital ratio of 203%. Murray described the current M&A pipeline as “positive,” noting that a reduction in private equity competition is opening up new opportunities in the UK and Benelux. He also commented on broader macroeconomic conditions, noting that despite some volatility, Chesnara’s long-term outlook remains stable due to natural hedges and long-duration contracts. Looking ahead to 2025, Murray reiterated Chesnara’s confidence in maintaining dividend growth, underpinned by strong visibility on future cash flows well above required commitments. For more CEO interviews and investor insights, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to our channel, and hit the notification bell so you never miss an update. #Chesnara #InsuranceStocks #DividendGrowth #MergersAndAcquisitions #CashGeneration #UKStocks #BeneluxMarkets #CanadaLifeDeal #FinancialResults #InvestorUpdates #ProactiveInvestors

Proactive - Interviews for investors

Light Science Technologies CEO on Injecta Fire Barrier solution to UK's unsafe cladding dilemma

Light Science Technologies Holdings PLC (AIM:LST) CEO Simon Deacon talked with Proactive's Stephen Gunnion about the significant opportunity surrounding the company’s Injecta Fire Barrier solution, particularly in light of ongoing fire safety issues in the UK’s residential building sector. Deacon highlighted that the UK still has more than 33,000 buildings between 11m and 18m in height, and over 11,000 high-risk buildings above 18m, that require urgent fire protection measures. He referenced a government estimate suggesting a potential £22 billion cost to address the cladding crisis, which has persisted since the Grenfell tragedy. The Injecta Fire Barrier, acquired in late 2023, offers what Deacon described as a "unique solution"—one that avoids facade removal by injecting fire-resistant material directly into cavities, providing over two hours of fire resistance. He said, "We're three times less in cost and much quicker to install than traditional methods." He noted the division secured £2.7 million in orders during 2024, performing strongly and receiving positive feedback for its efficiency and clean delivery. With an average order value over £500,000 and significant market scope, Deacon framed the opportunity as a scalable revenue driver for the group. The company is targeting £50 million in revenue over the next five years, with Injecta Fire Barrier expected to be a key growth driver. 👉 For more updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications for future content. #FireSafety #BuildingSafety #InjectaFireBarrier #LightScienceTechnologies #GrenfellLegacy #PropertyInvestment #ConstructionInnovation #FireProtection #CladdingCrisis #UKHousingSafety #ProactiveInvestors #SimonDeacon #BuildingRegulations #RealEstateSafety #PassiveFireProtection

Proactive - Interviews for investors

Atrato Partners on Social Housing REIT (SOHO): strategy, debt and dividend outlook

Atrato Partners, the newly appointed Investment Manager of Social Housing REIT (SOHO) talked with Proactive's Stephen Gunnion about the current state of the specialised supported housing sector and how the company is tackling key challenges within its portfolio. Fund manager Adrian D'Enrico was joined by Michael Carey and Natalie Markham, offering a comprehensive update on SOHO’s operational and financial performance. D'Enrico addressed common misconceptions about the sector, clarifying that it is not temporary or homeless accommodation, but instead provides long-term homes for adults with care needs. “A misconception as well is that specialised supported housing is a passive investment based on the long lease,” he explained, underlining the importance of resident occupancy and the operational real estate nature of the assets. Carey detailed the steps taken to resolve issues with Parasol and My Space Housing Solutions, including lease transfers to stronger providers, which are expected to improve rent collection. “We’ve collected 72% of the contracted amount so far with Westmoreland, and we’re confident we’ll meet our target,” he said. Markham reviewed the FY24 results, noting that while net tangible assets declined to £0.99 per share, rent collection stood at 93% and the company maintains strong debt metrics with an average maturity of 8.6 years and a 2.74% all-in cost. For more updates like this, head to Proactive's YouTube channel. Don’t forget to like this video, subscribe to the channel, and enable notifications so you never miss future content. #SocialHousing #REIT #AtratoPartners #SOHO #SpecialisedSupportedHousing #IncomeSecurity #RealEstateInvestment #DividendStocks #UKHousing #InvestorUpdate #PropertyPortfolio #ESGInvesting

Proactive - Interviews for investors

Opioid-Free pain relief: AFT’s global expansion strategy

AFT Pharmaceuticals Ltd Managing Director Dr Hartley Atkinson talked with Proactive at the AIM's Small and Midcap Conference about the company's unique approach to drug development, its expanding global footprint, and what lies ahead in 2025. AFT Pharmaceuticals is focused on creating pharmaceuticals "with a difference," targeting unmet needs and reducing reliance on opioids. “We don’t sell anything we don’t believe in,” said Dr Atkinson, highlighting the importance of alternatives to opioid treatments. One of the company’s key analgesic products helps avoid opioid use — a particularly timely innovation in light of the global opioid crisis. Dr Atkinson discussed the company’s core markets, with a strong presence in New Zealand and Australia, generating approximately 150 million in revenue. AFT also maintains operations in Asia and now exports to around 80 countries. The company has experienced sustained growth, having quadrupled in size over the past decade and doubled in the last five years. AFT has established six new affiliates across regions including Singapore, Hong Kong, South Africa, Canada, the UK, and Europe. Looking ahead, the company plans several product launches across Australia and New Zealand and anticipates five drug launches in China — the world’s second-largest pharmaceutical market. “For us, that’s going to be an interesting journey,” Atkinson added. #AFTPharmaceuticals #OpioidAlternatives #PharmaceuticalInnovation #ChinaPharma #DrugDevelopment #HealthcareGrowth #ASXStocks #BiotechInvesting #GlobalHealthcare #PharmaExpansion

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Gold Continues To Rise Past $3,120, Hitting All-Time Peak

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Gold Continues To Rise Past $3,120, Hitting All-Time Peak

Go Ad-Free